Efficacy and safety data on pretomanid for drug-resistant TB.

ABSTRACT:

Objective

To summarise the efficacy and safety of pretomanid (Pa) based regimens in patients with drug-resistant TB (DR-TB).

Methods

We included clinical trials, operational research and observational studies reporting the efficacy and safety of Pa-based regimens in DR-TB. The duration of the treatment was at least 24 weeks. Efficacy was reported as a favourable/unfavourable outcome and culture conversion. Safety was reported in terms of death and frequency of adverse events of special interest.

Results

Of the 127 articles identified, 13 were included. The proportion of favourable outcomes reported was 76-100%, and the median time to culture conversion was 4-6 weeks. Culture conversion rates ranged from 80-100% by the end of 3 months of treatment, regardless of the ty

SUBMITTER: Thuy HTT 

PROVIDER: S-EPMC11827665 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature